<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02476123</url>
  </required_header>
  <id_info>
    <org_study_id>0761-013</org_study_id>
    <nct_id>NCT02476123</nct_id>
  </id_info>
  <brief_title>Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid Tumors</brief_title>
  <official_title>Phase 1 Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Kirin Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kyowa Kirin Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the safety and tolerability and determine the
      maximum tolerated dose (MTD) or the recommended fixed dose of the combinations of
      Mogamulizumab and Nivolumab in subjects with locally advanced or metastatic solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">December 21, 2018</completion_date>
  <primary_completion_date type="Actual">February 7, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects reporting adverse events</measure>
    <time_frame>From the first dose of study medications until 90 days after the last dose of study medication</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects reporting serious adverse events</measure>
    <time_frame>From the first dose of study medications until 90 days after the last dose of study medication</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects reporting serious adverse events</measure>
    <time_frame>From the first dose of study medications until 90 days after the last dose of study medication</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects reporting adverse events</measure>
    <time_frame>From the first dose of study medications until 90 days after the last dose of study medication</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects experiencing dose-limiting toxicity</measure>
    <time_frame>For 28 days from the first dose of study medications</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Mogamulizumab+Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During parts 1 and 2, Mogamulizumab and Nivolumab are administered at appropriate intervals.
Part 1 (Dose Escalation Part) During Cohort 1 to 2, Mogamulizumab and Nivolumab are administered in combination.
Part 2 (Expansion Part) Patients will be treated with maximum tolerated dose established in the dose escalation part for each combination.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mogamulizumab: KW-0761, Nivolumab: (ONO-4538/BMS-936558)</intervention_name>
    <description>i.v. administration</description>
    <arm_group_label>Mogamulizumab+Nivolumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who voluntarily signed and dated Institutional Review Board approved informed
             consent form in accordance with regulatory and institutional guidelines.

          -  Subjects who have progressed or have been intolerant to any standard treatment regimen
             or refused standard treatment, or for which adequate standard therapy does not exist.

          -  Subjects who have evaluable lesion per guideline of Response Evaluation Criteria in
             Solid Tumors (RECIST) version 1.1.

          -  Subjects with life expectancy &gt; 12 weeks.

          -  Subjects with Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1.

          -  Potential child-bearing female who has agreed with contraception and not
             breast-feeding. For male who also has agreed with contraception.

          -  Subjects who have adequate hematological, renal, hepatic and respiratory functions
             defined.

          -  Must agree to present archival tumor tissues to sponsor or be willing to undergo a
             pre-treatment biopsy.

          -  Histologically or cytologically confirmed locally advanced or metastatic solid tumors.

        Exclusion Criteria:

          -  Female subjects who are pregnant or breast-feeding.

          -  Subjects with uncontrolled and significant inter-current illness.

          -  Subjects with known central nervous system (CNS) metastases and/or carcinomatous
             meningitis.

          -  Subjects who have been previously treated with an anti-programmed death 1 (PD-1),
             anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated
             antigen-4 (CTLA-4) antibody or any other antibody or drug specifically targeting
             T-cell co-stimulation or checkpoint pathways.

          -  Subjects who have been previously treated with Mogamulizumab.

          -  Subjects with any prior Grade â‰¥ 3 immune-related adverse event (irAE) while receiving
             any previous immunotherapy agent, or any unresolved irAE.

          -  Subjects with a history of severe hypersensitivity reactions to drugs.

          -  Subjects who have been received chemotherapies, immunotherapy, biologic or hormonal
             therapies, another investigational drug, radiation or major surgery for cancer
             treatment within 28 days or 42 days (for nitrosourea or mitomycin C) prior to Cycle 1
             Day 1.

          -  Subjects who have known active autoimmune disease or syndrome.

          -  Subjects who have active inflammatory bowel disease, irritable bowel disease, celiac
             disease, or other serious GI chronic conditions associated with diarrhea.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 10, 2015</study_first_submitted>
  <study_first_submitted_qc>June 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2015</study_first_posted>
  <last_update_submitted>June 9, 2019</last_update_submitted>
  <last_update_submitted_qc>June 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Mogamulizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

